Loading...
Derniers dépôts
-
Rodrigue S Allodji, Margaret A Tucker, Michael M Hawkins, Marie‐cécile Le Deley, Cristina Veres, et al.. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. International Journal of Cancer, 2020, 148 (9), pp.2079 - 2089. ⟨10.1002/ijc.33361⟩. ⟨inserm-04439010⟩
-
Maxime Enault, Véronique Minard-Colin, Nadège Corradini, Guy Leverger, Estelle Thebaud, et al.. Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, pp.64-78. ⟨10.1016/j.ejca.2021.10.025⟩. ⟨hal-04027205⟩
-
Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, et al.. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩. ⟨hal-03469622⟩
-
Othman Aissaoui, Jerome Phalippou, Abel Cordoba, Henri Azaïs, Lobna Ouldamer, et al.. Brachytherapy and surgery versus surgery alone for IB2 (FIGO 2018) cervical cancers: A FRANCOGYN study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2023, 290, pp.128-134. ⟨10.1016/j.ejogrb.2023.09.021⟩. ⟨hal-04336219⟩
-
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
-
Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, et al.. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales). European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩. ⟨hal-04242387⟩
-
Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, Marie Cécile Cécile Le Deley, Natasha K.A. van Eijkelenburg, et al.. A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?. Cancer Treatment Reviews, 2023, 120, pp.102625. ⟨10.1016/j.ctrv.2023.102625⟩. ⟨hal-04229528⟩
-
Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, et al.. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩. ⟨hal-04072026⟩
-
Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩
-
Véronique Vendrely, Philippe Ronchin, Mathieu Minsat, Karine Le Malicot, Claire Lemanski, et al.. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial. Radiotherapy & Oncology, 2023, 186, pp.109742. ⟨10.1016/j.radonc.2023.109742⟩. ⟨hal-04163679⟩
-
Manon Baty, David Pasquier, Khemara Gnep, Joël Castelli, Nolewenn Delaby, et al.. Achievable Dosimetric Constraints in Stereotactic Reirradiation for Recurrent Prostate Cancer. Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology, 2023, ⟨10.1016/j.prro.2023.05.007⟩. ⟨hal-04164898⟩